Company Filing History:
1 out of 523 
1 out of 202 Years Active: 2008
Title: John Jacobs - Innovator in Alzheimer's Treatment
Introduction
John Jacobs is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Alzheimer's disease. His innovative work has led to the development of compounds that target critical enzymes involved in the progression of this debilitating condition.
Latest Patents
John Jacobs holds a patent for 3,4-disubstituted, 3,5-disubstituted, and 3,4,5-substituted piperidines. This invention relates to substituted piperidine, piperazine, morpholine, and thiomorpholine compounds that are useful in treating Alzheimer's disease. Specifically, his compounds are designed to inhibit beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major component of the amyloid plaques found in the brains of Alzheimer's sufferers. One embodiment of the invention relates to compounds having a specific structure where Z is CR or N, and R, R, and R are as described in the specification. He has 1 patent to his name.
Career Highlights
Throughout his career, John Jacobs has worked with prominent companies in the pharmaceutical industry. He has been associated with Pharmacia & Upjohn Company and Elan Pharmaceuticals, Inc. His work in these organizations has allowed him to contribute to significant advancements in drug development.
Collaborations
John Jacobs has collaborated with notable colleagues, including Joseph B Moon and Shon R Pulley. These partnerships have further enhanced his research and development efforts in the pharmaceutical field.
Conclusion
John Jacobs is a dedicated inventor whose work has the potential to make a meaningful impact on the treatment of Alzheimer's disease. His innovative compounds and collaborations reflect his commitment to advancing medical science.